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A b s t r a c t
Introduction: Previous studies have examined the correlation between hy-
perandrogenemia and non-alcoholic fatty liver disease (NAFLD) in women 
and showed contradictory results. Therefore, we aimed to evaluate the rela-
tionship between testosterone level and Fatty Liver Index (FLI), as a surro-
gate marker for NAFLD, in a cohort of postmenopausal women.
Material and methods: A total of 150 postmenopausal women were includ-
ed in this cross-sectional study. Anthropometric and biochemical param-
eters, as well as blood pressure, were obtained. Non-alcoholic fatty liver 
disease is assessed by FLI, an algorithm based on body mass index, waist 
circumference, triglycerides and g-glutamyl transferase, as a simple and ac-
curate predictor of hepatic steatosis. Women were divided into three groups 
(FLI < 30, n = 80; 30 ≤ FLI < 60, n = 44; FLI ≥ 60, n = 26). Homeostasis model 
assessment of insulin resistance (HOMA-IR) as a surrogate marker of insulin 
resistance was calculated.
Results: Multiple linear regression analysis revealed that the best model 
consisted of 4 parameters (e.g., bioavailable testosterone (β = 0.288, p = 
0.001), log HOMA-IR (β = 0.227, p = 0.005), log high-sensitivity C-reactive 
protein (β = 0.322, p < 0.001), and retinol-binding protein 4 (β = 0.226, 
p < 0.001)). Adjusted R2 for the best model was 0.550, which means that as 
much as 55.0% of variation in FLI could be explained with this model.
Conclusions: Bioavailable testosterone is independently associated with FLI 
in postmenopausal women.
Key words: fatty liver, hyperandrogenemia, insulin resistance, obesity, 
postmenopausal.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the commonest form of 
a broad spectrum of conditions ranging from simple steatosis to inflam-
mation and fibrosis, resulting in non-alcoholic steatohepatitis and cirrho-
sis, and affects 20–30% of the general population [1].
Liver disease is an early predictor of diabetes mellitus type 2 (DM2) [2] 
and cardiovascular disease (CVD) [3].
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Recent reports show that the prevalence of 
NAFLD is higher in postmenopausal women than 
those in a  premenopausal state [4, 5] and that 
postmenopause is a risk factor for NAFLD [6]. One 
possible explanation may lie in the fact that women 
after menopause have increased insulin resistance 
(IR) and visceral abdominal fat, which are the major 
contributors to NAFLD development [4, 7].
Postmenopausal women experience estrogen 
deficiency and relative androgen excess, which 
might lead to redistribution of total body fat toward 
increase of visceral fat with consequent develop-
ment of IR [8]. It is speculated that not estrogen 
deficiency by itself, but rather androgen excess, 
might be the main culprit for such pathophysio-
logical changes, since exogenous administration of 
androgens to women has been demonstrated to 
lead to development of IR [8, 9]. On the other hand, 
administration of estradiol in postmenopausal 
women did not show any benefits [10, 11]. In line 
with this, the increased prevalence of NAFLD in pa-
tients with polycystic ovarian syndrome (PCOS) is 
explained by androgen excess, also [12].
Due to its invasive diagnostic nature, liver biop-
sy as the gold standard for NAFLD [13] has been 
replaced with abdominal ultrasonography, as the 
commonest technique for NAFLD assessment in 
clinical trials. In line with this, Bedogni et al. [14] 
developed the Fatty Liver Index (FLI), a simple and 
accurate predictor of hepatic steatosis that was 
derived in a general population-based study which 
highly correlated with abdominal ultrasonogra-
phy. It has been reported that NAFLD assessed by 
FLI was an independent risk factor for new-onset 
hypertension [1], DM2 [15], and CVD [16].
Previous studies have examined the correla-
tion between hyperandrogenemia and NAFLD and 
showed either no relationship [17, 18] or an inde-
pendent association between testosterone level 
and NAFLD [19, 20].
Taking all these contradictory results into ac-
count, the aim of our study was to evaluate the re-
lationship between testosterone level (e.g., total, 
free and bioavailable form) and FLI, as a surrogate 
marker for NAFLD, in a cohort of postmenopausal 
women. In addition, we aimed to examine a clus-
ter of other biomarkers (e.g., adipokines, inflam-
mation markers, insulin resistance markers and 
sex hormones) that might make a significant con-
tribution to fatty liver assessment.
Material and methods
Population
The study enrolled a  total of 150 postmeno-
pausal women (mean age: 56.6 ±4.8 years) who 
volunteered to participate in the study. Partic-
ipants were consecutively recruited in the study 
when seeking gynecologic healthcare in the Pri-
mary Health Care Center in Podgorica, Monte-
negro for their regular check-up, in the period 
from October 2012 to May 2013. Menopause is 
defined as the absence of menstrual bleeding for 
more than 1 year. All the participants completed 
a questionnaire including demographic character-
istics, somatic illnesses, smoking history and cur-
rent medications use. Medical history and clinical 
examinations were carried out on the same day.
Inclusion criteria were: menopausal status, no 
hormone replacement therapies, no signs and 
symptoms of acute inflammatory disease, no his-
tory or the presence of malignancy, and non-smok-
ing. Exclusion criteria were: ethanol consumption 
> 20 g/day, liver disease (cirrhosis, viral hepa-
titis, autoimmune hepatitis, primary sclerosing 
cholangitis, primary biliary cirrhosis and overlap 
syndromes, drug-induced liver disease, hemo-
chromatosis, Wilson’s disease, α1-antitrypsin de-
ficiency), diabetes mellitus, hypothyroidism or hy-
perthyroidism, renal dysfunction, cardiovascular 
disorders, and medications use (antihypertensive, 
lipid-lowering, hypoglycemic, anti-inflammatory 
medications, hormonal replacement therapy or 
any medications that can affect liver function) in 
the last 6 months.
Participants were instructed not to perform any 
vigorous physical activity the day before the blood 
samples were taken. All the participants provided 
written informed consent. The study protocol was 
approved by the Ethical Committee of Primary 
Health Care Center in Podgorica, Montenegro, and 
the research was carried out in compliance with 
the Declaration of Helsinki [21].
Anthropometric measurements
Basic anthropometric measurements – body 
height (cm), body weight (kg) and waist circum-
ference (WC) (cm) – were obtained in the morning. 
Weight was measured to the nearest 0.1 kg on 
a balance beam scale, with the subjects barefoot 
and with light clothing. Height was measured to 
the nearest 0.1 cm using a  wall-mounted stadi-
ometer, without shoes. Waist circumference was 
measured with non-stretchable tape over the un-
clothed abdomen at the midpoint between the 
lowest rib and the iliac crest. Measurements were 
made at the end of normal expiration. The tape 
was parallel to the floor and did not compress the 
skin. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters 
squared (kg/m2).
Although our obese postmenopausal women 
comprised slightly obese (overweight, 25 ≤ BMI 
< 30 kg/m2) and moderately obese subjects 
(30 ≤ BMI < 40 kg/m2), for reasons of simplicity, 
we referred to them as overweight/obese women.
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Blood pressure was measured with a sphygmo-
manometer after the subject had been seated for 
15 min. The average of three measurements taken 
on the right arm was recorded. All measurements 
were taken by the same trained evaluator.
Participants who met at least three of the fol-
lowing conditions were diagnosed with metabol-
ic syndrome (MetS): WC ≥ 80 cm, hyperglycemia 
≥ 5.6 mmol/l; high-density lipoprotein cholesterol 
(HDL-c) < 1.30 mmol/l; triglycerides ≥ 1.70 mmol/l 
and hypertension: systolic blood pressure (SBP) or 
diastolic blood pressure (DBP) ≥ 130/85 mm Hg [22].
Non-alcoholic fatty liver disease is assessed by 
the FLI, an algorithm based on body mass index, 
waist circumference, triglycerides and g-glutamyl 
transferase, as a  simple and accurate predictor 
of hepatic steatosis. The FLI was calculated for 
each individual subject in accordance with the 




Women were divided into three groups (FLI < 30, 
n = 80; 30 ≤ FLI < 60, n = 44; FLI ≥ 60, n = 26) [14].
Biochemical analyses
The blood samples were taken between 7 and 
9 a.m., after at least 8 h of overnight fast. Samples 
were left to clot for 30 min and then centrifuged at 
3000 rpm for 10 min. Serum samples were divid-
ed into aliquots and stored at –80°C, without prior 
thawing and re-freezing before analyses, except for 
glucose, which was determined immediately after 
the blood was drawn. Serum levels of glucose, to-
tal cholesterol (TC), HDL-c, low-density lipoprotein 
cholesterol (LDL-c), triglycerides (TG), albumin, uric 
acid, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and g-glutamyl transferase 
(GGT) were measured using standardized enzymat-
ic procedures, spectrophotometrically (Roche Co-
bas 400, Mannheim, Germany). Cystatin C, RBP4, 
and high-sensitivity C-reactive protein (hsCRP) 
levels were determined using a  nephelometric 
assay (Behring Nephelometer Analyzer, Marburg, 
Germany). Sex-hormone binding globulin (SHBG), 
total estradiol, total testosterone and insulin were 
measured by chemiluminescent immunometric as-
say (Immulite 2000, Siemens, Munich, Germany). 
Homeostasis model assessment of insulin resis-
tance (HOMA-IR) was calculated: HOMA-IR = fast-
ing glucose (mmol/l) × fasting insulin [µIU/l]/22.5 
[23]. Bioavailable testosterone was calculated, also 
(http://www.issam.ch/freetesto.htm) [24]. 
Statistical analysis
Statistical analysis was performed using the 
SPSS statistical package (version 15.0 for Win-
dows, SPSS, Chicago, IL, USA). Data are presented 
as mean ± standard deviation, or median (inter-
quartile range), or counts and percentages. Dif-
ferences between groups were evaluated with 
Student’s t test for normally or the Mann-Whitney 
test for non-normally distributed parameters or 
one-way analysis of variance (ANOVA) and Kru-
skal-Wallis non-parametric analysis of variance, 
where appropriate. The c2 test was used to analyze 
the differences in categorical data. Pearson’s (r) 
correlation coefficient was used to determine the 
relationships between FLI and other variables. Due 
to skewed distribution, log transformed HOMA-IR 
and hsCRP were used. Multiple linear regression 
(MLR) analysis was performed to identify indepen-
dent determinants of FLI. Receiver operating char-
acteristic (ROC) curve analysis was used with the 
purpose of testing the discriminatory potential of 
a group of parameters selected in MLR analysis, 
with FLI as the dependent variable. Construction 
of a model consisting of FLI formula independent 
parameters by using logistic regression analysis 
was also performed. In all analyses a p-value of 
< 0.05 was considered as statistically significant.
Results
Table I shows the general clinical and biochem-
ical characteristics of apparently healthy post-
menopausal women involved in this study. Signifi-
cantly higher BMI and WC (p < 0.001, respectively), 
fasting glucose (p = 0.003), insulin and HOMA-IR 
(p < 0.001, respectively), LDL-c (p = 0.015), tri-
glycerides, GGT and ALT activity, SBP, and DBP 
(p < 0.001, respectively), but lower HDL-c (p < 
0.001), were observed in women with a higher FLI 
level as compared with the low FLI level group. Fur-
thermore, we also found a significant difference in 
several other cardiometabolic parameters, which 
are independent of FLI calculation, i.e., a  signifi-
cantly higher level of uric acid, hsCRP, cystatin C 
(p < 0.001, respectively), and RBP4 (p = 0.001) 
among women in the higher FLI level group, as com-
pared with women in the low FLI level group. More-
over, a significantly higher number of obese individ-
uals (c2 = 57.29; p < 0.001), as well as individuals 
with MetS (c2 = 53.24; p < 0.001), was found in the 
group with the highest FLI. There was no difference 
with respect to age, TC level, AST activity, albumin, 
total estradiol or testosterone level between groups.
Next, we performed Pearson’s correlation in 
order to examine the potential relationship be-
tween FLI level and cardiometabolic parameters 
independent of FLI calculation (LDL-c, glucose, in-
sulin, HOMA-IR, cystatin C, RBP4, hsCRP, uric acid, 
ALT, free and bioavailable testosterone, SHBG, SBP 
and DBP) in the whole group of apparently healthy 
postmenopausal women.
Pearson’s correlation revealed a  significant 
positive relationship between FLI and LDL-c 
Bioavailable testosterone is independently associated with Fatty Liver Index in postmenopausal women
Arch Med Sci 5, August / 2017 1191
(p = 0.002), log HOMA-IR, cystatin C, RBP4, uric 
acid, bioavailable testosterone, SHBG, ALT activity 
and SBP (p < 0.001, respectively), as well as a sig-
nificant negative relationship between FLI and 
HDL-c (p < 0.001) (Table II). 
Multiple linear regression (MLR) analysis was 
performed to identify which of the measured 
markers have the best association with FLI. Name-
ly, all variables found to have a  significant pre-
dictive value in Pearson’s correlation (e.g., ALT, 
Table I. General characteristics of studied postmenopausal women divided according to Fatty Liver Index level
Parameter FLI < 30
(n = 80)





Age [years] 56.0 ±4.90 57.3 ±4.39 57.5 ±5.22 0.203
BMI [kg/m²] 23.6 ±2.93aaa,bbb 27.9 ±1.88aaa 32.8 ±2.70 < 0.001
WC [cm] 80.2 ±7.40aaa,bbb 95.7 ±5.80aaa 104.5 ±8.29 < 0.001
Glucose [mmol/l] 5.24 ±0.39aaa 5.39 ±0.53 5.63 ±0.72 0.003
TC [mmol/l] 6.31 ±0.99a 6.60 ±1.18 6.76 ±0.97 0.104
HDL-c [mmol/l] 1.85 ±0.43aaa,bb 1.62 ±0.32aaa 1.34 ±0.27 < 0.001
LDL-c [mmol/l] 4.09 ±0.95aa,bb 4.51 ±1.16 4.65 ±0.84 0.015
TG [mmol/l]# 1.06 (0.79–1.41)aaa,bb 1.42 (0.99–1.83)aaa 2.31 (1.40–2.45) < 0.001
Insulin [µIU/l]# 4.90 (3.89–5.98)aaa,bbb 8.92 (6.53–10.79)a 10.05 (7.88–14.40) < 0.001
HOMA-IR# 1.10 (0.90–1.42)aaa,bbb 2.01 (1.54–2.78)a 2.67 (1.81–3.64) < 0.001
SBP [mm Hg] 119 ±23.1aaa,bbb 139 ±20.0 148 ±18.0 < 0.001
DBP [mm Hg] 57.8 ±14.2aaa,bbb 91.2 ±9.7 106 ±10.4 < 0.001
AST [U/l] 18 (16–20) 18 (16–21) 18 (15–22) 0.986
ALT [U/l] 16 (13–20)aaa,bbb 21 (15–24) 23 (17–28) < 0.001
GGT [U/l] 10.0 (8.0–12.5)aaa,bbb 13.0 (10.0–16.0)aa 15.5 (13.0–21.0) < 0.001
RBP4 [mg/l] 38.8 ±9.34aaa 42.1 ±8.63a 46.0 ±6.38 0.001
Cystatin C [mg/l] 0.73 ±0.09aaa,bbb 0.79 ±0.10aaa 0.85 ±0.10 < 0.001
HsCRP [mg/l] 0.53 (0.28–1.20)aaa,bbb 1.39 (0.94–2.56)a 1.91 (1.16–3.23) < 0.001
Uric acid [µmol/l] 234 ±54.6aaa,bbb 273 ±54.5aaa 330 ±53.1 < 0.001
Albumin [g/l] 46.6 ±2.34 47.4 ±2.67 47.0 ±2.73 0.125
Estradiol [pmol/l]# 53.5 (39.6–68.1) 54.5 (41.0–69.0) 53.0 (41.0–69.0) 0.961
Total T [nmol/l]# 1.00 (0.77–1.24) 1.01 (0.81–1.33) 1.10 (0.81–1.23) 0.942
Free T (%)# 1.04 (0.90–1.18)aaa,bbb 1.32 (1.13–1.63)aa 1.58 (1.39–1.80) < 0.001
Bioavailable T (%)# 25.5 (23.0–29.7)aaa,bbb 34.15 (29.4–40.4)aa 39.9 (36.2–48.8) < 0.001
SHBG [nmol/l] 74.67 ±17.93aaa,bbb 51.37 ±17.02aa 38.81 ±13.35 < 0.001
Overweight/obese, n (%) 30 (37.5) 44 (100) 26 (100) c2 = 53.23
< 0.001
Normal weight, n (%) 50 (62.5) 0 (0) 0 (0)
MetS (+), n (%) 5 (6.3) 26 (59) 20 (77) c2 = 57.29
< 0.001
MetS (–), n (%) 75 (93.7) 18 (41) 6 (23)
aaap < 0.001, aap < 0.01, ap < 0.05 vs. third group; bbbp < 0.001, bbp < 0.01, bp < 0.05 vs. Second group. Data are presented as mean ± 
standard deviation or #data with non-Gaussian distribution are shown as median values (interquartile range), or counts and percentages; 
*p-value from one-way ANOVA or Kruskal-Wallis non-parametric analysis of variance, followed by non-parametric Mann-Whitney U test, 
where appropriate; FLI – fatty liver index, BMI – body mass index, WC – waist circumference, HOMA-IR – homeostasis model assessment 
of insulin resistance, TC – total cholesterol, HDL-c – high-density lipoprotein cholesterol, LDL-c – low-density lipoprotein cholesterol, 
TG – triglycerides, AST – aspartate aminotransferase, ALT – alanine aminotransferase, HsCRP – high-sensitivity C-reactive protein, 
SBP – systolic blood pressure, DBP – diastolic blood pressure, T – testosterone, SHBG – sex-hormone binding globulin, MetS (+) – 
postmenopausal women with metabolic syndrome, MetS (–) – postmenopausal women without metabolic syndrome.
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SBP, LDL-c, bioavailable testosterone, HOMA-IR, 
uric acid, hsCRP, cystatin C and RBP4) were fur-
ther analyzed in MLR analysis for FLI prediction. 
Backward selection enabled us to find the best 
model consisting of 4 parameters (e.g., bioavail-
able testosterone (β = 0.288, p = 0.001), log HO-
MA-IR (β = 0.227, p = 0.005), log hsCRP (β = 0.322, 
p < 0.001), and RBP4 (β = 0.226, p < 0.001)). Adjust-
ed R2 for the best model was 0.550, which means 
that as much as 55.0% of variation in FLI could be 
explained with this model (Tables III and IV).
After that, we conducted a  receiver operating 
characteristic (ROC) analysis of selected parame-
ters to test their discriminatory ability regarding 
FLI level (low vs. higher level). Additionally, we 
constructed a model consisting of those 4 param-
eters (bioavailable testosterone, log HOMA-IR, log 
hsCRP and RBP4) by using logistic regression anal-
ysis generated predictive probabilities. Figure 1 
shows the ROC curve graph and Table V shows the 
most important ROC parameters: area under the 
curve (AUC) with 95% confidence interval (CI) of 
selected parameters and the model. Table V also 
shows sensitivities, specificities and cut-off values 
for selected parameters.
Comparison of ROC curves showed that all 
separate curves have comparable discriminatory 
capability towards FLI level status. Construction 
of a  model consisting of those 4 FLI formula in-
dependent parameters (bioavailable testosterone, 
log HOMA-IR, log hsCRP and RBP4) by using logis-
tic regression analysis showed that the new ROC 
curve had outstanding discriminatory capability 
(AUC = 0.990, according to Hosmer and Leme-
show’s rules) [25].
Discussion
To our knowledge, this is the first study to ex-
amine a  cluster of biomarkers (e.g., adipokines, 
inflammation markers, insulin resistance markers 
and sex hormones) that can make a  significant 
contribution to fatty liver assessment. We found 
several biomarkers that are independently asso-
ciated with FLI, such as bioavailable testosterone, 
insulin resistance as measured by HOMA-IR, RBP4 
and hsCRP, showing that as much as 55.0% of vari-
ation in FLI could be explained with this model. 
Furthermore, the current study has demonstrated 
that the multimarker approach could be of great 
benefit in order to identify those postmenopausal 
women with higher FLI. Namely, construction of 
a  model consisting of those 4 FLI formula inde-
pendent parameters (bioavailable testosterone, 
log HOMA-IR, log hsCRP and RBP4) by using logis-
tic regression analysis showed that the new ROC 
curve had outstanding discriminatory capability, 
according to Hosmer and Lemeshow’s rules (Fig-
ure 1 B).
The NAFLD represents the hepatic manifestation 
of MetS [1]. In line with this, in our study we reported 
a significantly higher number of obese postmeno-
pausal women, as well as women with MetS status, 
in the highest FLI group, as compared to the low FLI 
Table II. Pearson’s correlation (r) of log trans-
formed Fatty Liver Index and examined parameters 
independent of FLI calculation
Variable r P-value
Age [years] 0.107 0.192
Glucose [mmol/l] 0.347 < 0.001
Log HOMA-IR 0.600 < 0.001
TC [mmol/l] 0.155 0.058
LDL-c [mmol/l] 0.255 0.002
HDL-c [mmol/l] –0.575 < 0.001
Uric acid [µmol/l] 0.543 < 0.001
Log hsCRP [mg/l] 0.526 < 0.001
Cystatin C [mg/l] 0.387 < 0.001
RBP4 [mg/l] 0.332 < 0.001
ALT [U/l] 0.318 < 0.001
Albumin [g/l] 0.045 0.581
SBP [mm Hg] 0.497 < 0.001
DBP [mm Hg] 0.485 < 0.001
Total estradiol [pmol/l] –0.050 0.544
Total testosterone [nmol/l] –0.067 0.417
Free testosterone (%) 0.622 < 0.001
Bioavailable testosterone (%) 0.631 < 0.001
SHBG [nmol/l] –0.641 < 0.001
Log HOMA-IR – logarithmically transformed homeostasis model 
assessment of insulin resistance, TC – total cholesterol, HDL-c 
– high-density lipoprotein cholesterol, LDL-c – low-density lipo- 
protein cholesterol, ALT – alanine aminotransferase, Log hsCRP 
– logarithmically transformed high sensitivity C-reactive protein, 
RBP4 – retinol-binding protein 4, SBP – systolic blood pressure, 
SHBG – sex-hormone binding globulin.
Table III. Multiple linear regression R coefficients 
in the best-fit model for the association of several 
parameters with log FLI as dependent variable
Model summary
Model R R2 Adjusted R2 Std. error of 
the estimate
1 0.631a 0.398 0.394 0.34468
2 0.691b 0.478 0.471 0.32206
3 0.733c 0.538 0.528 0.30404
4 0.750d 0.562 0.550 0.29679
aPredictors: (Constant), Bioavailable testosterone. bPredictors: 
(Constant), Bioavailable testosterone, logCRP. cPredictors: (Constant), 
Bioavailable testosterone, logCRP, RBP4. dPredictors: (Constant), 
Bioavailable testosterone, logCRP, RBP4, logHOMA-IR.
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group. Moreover, all normal weight women were in 
the low FLI group, suggesting that obese state may 
greatly influence the hepatic steatosis state.
Visceral adipose tissue is a  significant source 
of free fatty acids which reach the liver through 
the portal vein, thus having a great influence on 
fatty liver development [12]. In addition, IR and 
compensatory hyperinsulinemia also contribute 
to increased hepatic lipogenesis. The enlargement 
of visceral adipose tissue is also accompanied by 
Figure 1. A – ROC curves of selected parameters’, B – ROC curve of model consisting of 4 selected parameters’ 
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Table IV. Multiple linear regression standardized β coefficients and p-values for the parameters in the best-fit 
model for the association of several parameters with log FLI as dependent variable
Coefficientsa





1 (Constant) 0.348 0.102 3.402 0.001
Bioavailable testosterone 0.031 0.003 0.631 9.885 < 0.001
2 (Constant) 0.557 0.105 5.292 < 0.001
Bioavailable testosterone 0.024 0.003 0.497 7.526 < 0.001
Log hsCRP 0.312 0.066 0.313 4.745 < 0.001
3 (Constant) 0.146 0.137 1.067 0.288
Bioavailable testosterone 0.021 0.003 0.438 6.865 < 0.001
Log hsCRP 0.338 0.062 0.339 5.424 < 0.001
RBP4 0.012 0.003 0.251 4.352 < 0.001
4 (Constant) 0.350 0.152 2.311 0.022
Bioavailable testosterone 0.014 0.004 0.288 3.551 0.001
Log hsCRP 0.321 0.061 0.322 5.247 < 0.001
RBP4 0.011 0.003 0.226 3.968 < 0.001
Log HOMA-IR 0.421 0.147 0.227 2.867 0.005
aDependent variable: log FLI, Log HOMA-IR – logarithmically transformed homeostasis model assessment of insulin resistance, Log hsCRP 
–  logarithmically transformed high-sensitivity C-reactive protein, RBP4 – retinol-binding protein 4.
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Table V. Area under the curve, 95% confidence interval and standard error for the parameters of selected parame-
ters’ discriminatory ability regarding Fatty Liver Index level (low vs. higher risk); pairwise comparison of the areas 
under ROC curves (AUCs) for model and separate parameters  







Model (4 parameters) 0.990 0.977–1.003 0.007 – – – < 0.001
Bioavailable testosterone 0.868 0.803–0.933 0.033 96 55 27.65 < 0.001
Log HOMA-IR 0.850 0.783–0.917 0.034 96 45 1.43 < 0.001
Log hsCRP 0.758 0.676–0.840 0.042 96 53 –0.14 < 0.001
RBP4 0.729 0.639–0.819 0.046 96 94 26.50 < 0.001
AUC – area under ROC curve, CI – confidence interval, SE – standard error, Model: Bioavailable testosterone, Log HOMA-IR – logarithmically 
transformed homeostasis model assessment of insulin resistance, Log hsCRP – logarithmically transformed high sensitivity C-reactive 
protein, RBP4 – retinol-binding protein 4. *P from pairwise comparison for AUC differences between Model and separate parameter.
chronic low-grade inflammation and monocyte 
infiltration, leading to dysregulation of secretion 
of pro-inflammatory cytokines (tumor necrosis 
factor-α (TNF-α), interleukin-6 (IL-6), CRP) [3, 26] 
and adipokines (e.g., increased levels of leptin and 
RBP4 and decreased levels of adiponectin) that 
modulate insulin sensitivity [12].
Inflammation plays a key role in the pathogen-
esis of NAFLD [3]. Bhatia et al. [27] demonstrated 
that an increase in CRP was an independent risk 
factor for NAFLD, which is in line with our results.
Even though RBP4 originates from the liver 
and is closely related to adiposity, IR and liver fat 
[28], no clear link has been established between 
RBP4 and NAFLD severity [29, 30].
The current study demonstrated an indepen-
dent association between RBP4 and FLI, which is 
also consistent with the results in a pediatric pop-
ulation [31].
Although we did not report any difference in to-
tal estradiol and total testosterone level between 
groups, we observed higher free and bioavailable 
testosterone in the high FLI group. Our results 
were similar to the results obtained by Polyzos 
et al. [32], who also reported no difference in se-
rum total estradiol and testosterone level between 
women with NAFLD and the control group, but re-
ported higher free and bioavailable testosterone 
levels in postmenopausal women with NAFLD. 
All these data demonstrated that androgen ex-
cess, which is the main feature of PCOS and post-
menopause, and is interrelated to IR, may be an 
additional contributing factor to NAFLD develop-
ment [12].
Previous studies have examined the correla-
tion between hyperandrogenemia and NAFLD and 
showed either no relationship [17, 18] or an inde-
pendent association between testosterone level 
and NAFLD [19, 20].
Macut et al. [17] reported no independent cor-
relation between free androgen index and NAFLD 
in PCOS women, suggesting that the association 
between elevated androgen levels and NAFLD is 
mediated by IR. They speculated that IR aggra-
vates hyperandrogenemia by increasing ovarian 
androgen synthesis and by down-regulating he-
patic SHBG production, establishing a  positive 
feedback loop between increased circulating lev-
els of free androgens and more pronounced IR in 
patients with PCOS.
In concordance with Macut et al. [17], IR evalu-
ated with the HOMA-IR was independently asso-
ciated with NAFLD in our population. IR is associ-
ated with impaired suppression of lipolysis in the 
adipose tissue, leading to an increased influx of 
free fatty acids to the liver and consequent hepat-
ic steatosis [33].
However, in our study in MLR, bioavailable tes-
tosterone was independently associated with FLI, 
suggesting that androgen excess in postmeno-
pausal women could be an additional fatty liver 
risk factor, independently of IR.
In a population of men with NAFLD, lower total 
and free testosterone levels were independently 
associated with NAFLD  [34], thus confirming the 
paradox in understanding the relationship of cir-
culating androgen levels with metabolic disorders 
and NAFLD. Namely, low total and free testosterone 
are also associated with MetS and DM2 in men, 
whereas high total and free androgens are associ-
ated with MetS and IR in women with PCOS [35]. 
Similarly, increased free testosterone was related 
to higher risk of MetS and is strongly related to ab-
dominal obesity in postmenopausal women [36]. 
Bioavailable testosterone may play an import-
ant role in menopause-related redistribution of 
fat towards the central abdominal region. Janssen 
et al. [37] demonstrated that women with more 
rapidly changing bioavailable testosterone expe-
rienced a  larger increase in adiposity compared 
with their more stable counterparts, suggesting 
that the relationship between increased bioavail-
able testosterone and adipose tissue may be 
key in the understanding of hormonal changes 
observed during the menopausal transition that 
links obesity to fatty liver risk.
Our study has some limitations. The small 
number of postmenopausal women included in 
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the current cross-sectional study may affect the 
results. Furthermore, the causal relationship be-
tween FLI and bioavailable testosterone in post-
menopausal women could not be established. 
Furthermore, we excluded the potential influence 
of medications on the obtained results, since we 
included only those women who did not receive 
any medications in the last 6 months. However, it 
could be interesting in some future studies to ex-
amine the influence of medications on the results 
obtained in the current study.
In conclusion, bioavailable testosterone is in-
dependently associated with the FLI in postmeno-
pausal women. Prospective studies are needed for 
a better understanding of the mechanisms of the 
relationship between increased androgenicity in 
postmenopausal women and non-alcoholic fatty 
liver disease in order to find better targeted ther-
apy for decreased risk and consequences of fatty 
liver status in this population group.
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